Safety of low lipoprotein(a) levels: the FOURIER trial

Eur Heart J. 2026 Jun 3:ehag398. doi: 10.1093/eurheartj/ehag398. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for pati

B Baris Gencer

Exercise mimetics: molecular mechanisms, biological and therapeutic effects

Mol Biomed. 2026 Jun 3;7(1):81. doi: 10.1186/s43556-026-00483-8.ABSTRACTAccumulating evidence underscores the therapeutic benefits of exercise in the prevention and treatment of various diseases. However, many patients are unable to engage in sufficient physical training because of frailty, disabili

J Jienan Zhang

Old and New Lines of Therapy Targeting Lipoprotein(a)

Curr Atheroscler Rep. 2026 Jun 3;28(1):59. doi: 10.1007/s11883-026-01419-x.ABSTRACTPURPOSE OF REVIEW: Elevated lipoprotein(a) (Lp[a]) is a prevalent, lifelong, and genetically determined causal cardiovascular risk factor, associated with a wide spectrum of cardiovascular disease, including atheroscl

K Khalil Anchouche

Atrial Synchrony Restored With Bachmann Bundle Pacing

JACC Case Rep. 2026 Jun 3:108744. doi: 10.1016/j.jaccas.2026.108744. Online ahead of print.ABSTRACTCASE SUMMARY: Capturing intrinsic interatrial conduction with Bachmann bundle (BB) pacing is known as a more physiological atrial pacing strategy than conventional right atrial appendage pacing. We pre

A Amarpal Karamjit Singh